Laserfiche WebLink
DocuSign Envelope ID:040056EC-0D41-4D98-9C65-E01AE876A6AB <br /> including, but not limited to approaches modeled on the Arrestee Drug <br /> Abuse Monitoring("ADAM') system. <br /> 8. Qualitative and quantitative research regarding public health risks and <br /> harm reduction opportunities within illicit drug markets, including surveys <br /> of market participants who sell or distribute illicit opioids. <br /> 9. Geospatial analysis of access barriers to MOUD and their association with <br /> treatment engagement and treatment outcomes. <br /> M. POST-MORTEM <br /> 1. Toxicology tests for the range of opioids, including synthetic opioids, seen in <br /> overdose deaths as well as newly evolving synthetic opioids infiltrating the drug <br /> supply. <br /> 2. Toxicology method development and method validation for the range of synthetic <br /> opioids observed now and in the future, including the cost of installation, <br /> maintenance, repairs and training of capital equipment. <br /> 3. Autopsies in cases of overdose deaths resulting from opioids and synthetic <br /> opioids. <br /> 4. Additional storage space/facilities for bodies directly related to opioid or synthetic <br /> opioid related deaths. <br /> 5. Comprehensive death investigations for individuals where a death is caused by or <br /> suspected to have been caused by an opioid or synthetic opioid overdose, whether <br /> intentional or accidental (overdose fatality reviews). <br /> 6. Indigent burial for unclaimed remains resulting from overdose deaths. <br /> 7. Navigation-to-care services for individuals with opioid use disorder who are <br /> encountered by the medical examiner's office as either family and/or social <br /> network members of decedents dying of opioid overdose. <br /> 8. Epidemiologic data management and reporting to public health and public safety <br /> stakeholders regarding opioid overdose fatalities. <br /> 13 <br />